Natural Alternatives International, Inc.

As of February 13, 2024, Natural Alternatives International, Inc. is considered risky and overvalued due to significant losses and poor return metrics, with a much lower EV to EBITDA ratio compared to peers, and a 1-year stock return of -49.46% versus the S&P 500's 17.14%.

As of October 1, 2023, Natural Alternatives International, Inc. is considered attractive due to its undervalued status, with a P/E ratio of 15.2, a P/B ratio of 1.8, and a 12% ROE, making it more favorable compared to peers like Herbalife and USANA, alongside strong recent stock performance.

As of October 3, 2023, there is insufficient technical data for Natural Alternatives International, Inc. to determine a bullish or bearish outlook.

As of March 2022, the management team of Natural Alternatives International, Inc. includes Mr. Mark LeDoux as Chairman and CEO, along with independent directors Mr. Joe Davis, Mr. Alan Dunn, Mr. Alan Lane, and Mr. Lee Weldon.

Natural Alternatives International, Inc. formulates, manufactures, and markets nutritional supplements in the Pharmaceuticals & Biotechnology industry, with a market cap of $32.36 million and quarterly net sales of $29 million but a net profit of -$2 million as of March 2025.

As of Jun 18, Natural Alternatives International, Inc. has a market capitalization of 32.36 million, with net sales of 125.35 million and a net profit of -8.23 million over the latest four quarters. As of Jun 24, the company reported shareholder's funds of 82.59 million and total assets of 171.74 million.